The landscape of metabolic and obesity research has experienced a seismic shift in 2026. While dual-agonist peptides like tirzepatide dominated the scientific conversation in recent years, the emergence of **retatrutide** (LY3437943) has redefined the boundaries of multi-hormonal pharmacotherapy. According to recent search analytics, retatrutide has become one of the most highly researched compounds in the […]
